PUBLIC LAW 117–8—APR. 23, 2021  135 STAT. 254  Public Law 117–8  117th Congress  An Act  To educate health care providers and the public on biosimilar biological products,  and for other purposes.  Be it enacted by the Senate and House of Representatives of  the United States of America in Congress assembled,  Apr. 23, 2021  [S. 164]  42 USC 201 note.  Advancing  Education on  Biosimilars Act  of 2021.  This Act may be cited as the ‘‘Advancing Education on  Biosimilars Act of 2021’’.  Subpart 1 of part F of title III of the Public Health Service  Act (42 U.S.C. 262 et seq.) is amended by adding at the end  the following:  ‘‘(a) INTERNET WEBSITE.—  ‘‘(1) IN GENERAL.—The Secretary may maintain and operate  an internet website to provide educational materials for health  care providers, patients, and caregivers, regarding the meaning  of the terms, and the standards for review and licensing of,  biological products, including biosimilar biological products and  interchangeable biosimilar biological products.  ‘‘(2) CONTENT.—Educational materials provided under  paragraph (1) may include—  ‘‘(A) explanations of key statutory and regulatory  terms, including ‘biosimilar’ and ‘interchangeable’, and  clarification regarding the use of interchangeable biosimilar  biological products;  ‘‘(B) information related to development programs for  biological products, including biosimilar biological products  and interchangeable biosimilar biological products and rel- evant clinical considerations for prescribers, which may  include, as appropriate and applicable, information related  to the comparability of such biological products;  ‘‘(C) an explanation of the process for reporting adverse  events for biological products, including biosimilar  biological products and interchangeable biosimilar biological products; and  ‘‘(D) an explanation of the relationship between bio- similar biological products and interchangeable biosimilar  biological products licensed under section 351(k) and ref- erence products (as defined in section 351(i)), including  the standards for review and licensing of each such type  of biological product.  42 USC 263–1.  SECTION 1. SHORT TITLE.  SEC. 2. EDUCATION ON BIOLOGICAL PRODUCTS.  ‘‘SEC. 352A. EDUCATION ON BIOLOGICAL PRODUCTS. 